Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Immune responses are tightly regulated via signaling through numerous co-stimulatory and
co-inhibitory molecules. Exploitation of these immune checkpoint pathways is one of the …

Background KRAS and BRAF mutations are well-established predictive and prognostic
factors in metastatic colorectal cancer; however, their impact in the adjuvant setting has not …

Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …

Importance The data reported herein were accepted for assessment by the US Food and
Drug Administration for Biologics License Application under priority review to establish the …

Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …

Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To …

Background Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of
pretreated patients with advanced gastric cancer done in Japan. We investigated whether …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …